NCT04091750 2026-03-03
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Georgetown University
Phase 2 Active not recruiting
Clinical Trials
35 trialsNCT03468218 2026-01-23
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
Emory University
Phase 2 Active not recruiting
NCT04022343 2026-01-05
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
Phase 2 Active not recruiting
NCT05052723 2025-11-19
Cabozantinib and Pembrolizumab in Metastatic Pancreas
University of Kentucky
Phase 2 Completed
NCT04164979 2025-08-11
Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma
University of California, Irvine
Phase 2 Active not recruiting
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01441947 2025-05-25
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04316182 2025-03-30
ACTION
Fundacion Clinic per a la Recerca Biomédica
Phase 2 Completed
NCT03149822 2025-03-13
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Phase 1/2 Completed
NCT03370718 2024-12-10
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03534804 2024-11-26
PemCab
University of Utah
Phase 2 Completed
NCT05200143 2024-09-19
Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma
Providence Health & Services
Phase 2 Terminated
NCT01466036 2024-03-05
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02795156 2023-12-05
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03201250 2023-09-08
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
University of Nebraska
Phase 1/2 Terminated
NCT02101736 2023-05-24
NF105-CABO
University of Alabama at Birmingham
Phase 2 Completed
NCT02036476 2023-05-09
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT04442581 2023-04-05
Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer
University of Washington
Phase 2 Terminated
NCT02885324 2022-10-06
Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
Indiana University
Phase 2 Terminated
NCT03542877 2022-07-15
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
University of Colorado, Denver
Phase 2 Completed
NCT03964337 2022-06-29
SPARC
Duke University
Phase 2 Terminated
NCT01630590 2022-03-25
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01812668 2021-08-05
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT03630120 2021-07-14
Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT02260531 2021-05-20
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02132598 2021-03-10
Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases
University of Pittsburgh
Phase 2 Terminated
NCT01588821 2020-09-29
Cabozantinib in Advanced Solid Malignancies
Massachusetts General Hospital
Phase 2 Completed
NCT01599793 2020-03-26
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
University of Chicago
Phase 2 Completed
NCT01703065 2018-12-04
Cabozantinib in Men With Castration-Resistant Prostate Cancer
University of Washington
Phase 2 Terminated
NCT01663272 2018-09-19
A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT01428219 2017-12-12
Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
University of Michigan Rogel Cancer Center
Phase 2 Terminated
NCT01866293 2017-08-30
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT01954745 2017-02-03
Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT01738438 2016-12-06
Cabozantinib for Metastatic Triple Negative BrCa
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01347788 2016-11-28
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Massachusetts General Hospital
Phase 1 Completed